Please assess the completion status of the following clinical trial:

Trial Title: A Study in Patients With Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of Erectile Dysfunction (ED) of at least 3 months duration.~* Anticipate having the same adult female sexual partner during the study.~* Agree not to use any other treatment for ED and to participate in recording responses to questionnaires and other instruments used in this study.~Exclusion Criteria:~* Previous or current treatment with tadalafil or any other phosphodiesterase type 5 (PDE5) inhibitor.~* ED caused by other primary sexual disorders, history of radical prostatectomy or other pelvic surgery with subsequent failure to achieve any erection, or history of penile implant or clinically significant penile deformity.~* ED caused by untreated or inadequately treated endocrine disease.~* Current treatment with doxazosin, nitrates, cancer chemotherapy, or anti-androgens.~* Severe renal or hepatic impairment, history of malignant hypertension.~* Presence or history of specific heart conditions.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil on demand (Type: EXPERIMENTAL): 10 milligrams (mg) or 20 mg on demand
- Tadalafil once a day (Type: EXPERIMENTAL): 5 mg or 2.5 mg once a day
- Sildenafil Citrate (Type: ACTIVE_COMPARATOR): 50 mg, 100 mg, or 25 mg on demand

Based on this trial design, predict the completion outcome and termination type (if applicable).